Updated stage 1 data from the PRESERVE-003 Phase 3 trial report a median overall survival of 18.5 months with the conditionally active CTLA-4 antibody gotistobart versus 10.0 months with docetaxel in previously treated metastatic squamous non-small cell lung cancer (hazard ratio 0.56, nominal p=0.0295). Grade 3 or higher treatment-related adverse events occurred at similar rates in both arms, 44.4% versus 48.8%. The cohort comprised only 87 randomized patients in a non-pivotal stage, with the pivotal stage 2 still enrolling across more than 160 sites.
Key Points
- Median survival 18.5 months versus 10.0 with docetaxel
- Hazard ratio 0.56; nominal p-value 0.0295, 87 patients
- Severe treatment-related toxicity comparable to chemotherapy, 44.4% versus 48.8%
Longevity Analysis
Checkpoint inhibition designed to activate preferentially within the acidic tumor microenvironment reflects a broader shift in oncology toward directing immune surveillance while limiting collateral damage to healthy tissue — a distinction that matters as much for function and recovery capacity after treatment as for survival duration. Comparable severe toxicity alongside an eight-month survival difference suggests the therapeutic advantage here comes from more precise immune targeting rather than greater intensity. The small, non-pivotal sample and nominal statistical threshold require the pivotal stage to confirm the effect before the result carries clinical weight.
Original published by LT Wire.